Medical therapies for hypertrophic cardiomyopathy: Current state of the art.

[1]  I. Olivotto,et al.  Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy , 2023, Journal of clinical medicine.

[2]  Gregory A. Newby,et al.  Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice , 2023, Nature Medicine.

[3]  M. Wheeler,et al.  Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption , 2023, JAMA cardiology.

[4]  N. Smedira,et al.  Survival After Septal Reduction in Patients >65 Years Old With Obstructive Hypertrophic Cardiomyopathy. , 2023, Journal of the American College of Cardiology.

[5]  C. Kramer,et al.  Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2023, Journal of the American College of Cardiology.

[6]  N. Smedira,et al.  Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study , 2022, Circulation. Cardiovascular imaging.

[7]  T. B. Rasmussen,et al.  Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy. , 2022, Journal of the American Society of Echocardiography.

[8]  N. Smedira,et al.  Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. , 2022, Journal of the American College of Cardiology.

[9]  I. Olivotto,et al.  Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter , 2022, Journal of the American Heart Association.

[10]  T. B. Rasmussen,et al.  Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2021, Journal of the American College of Cardiology.

[11]  E. Chin,et al.  Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. , 2021, Journal of medicinal chemistry.

[12]  J. Spertus,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet.

[13]  M. Desai,et al.  Unmet needs in the treatment of hypertrophic cardiomyopathy. , 2021, Future cardiology.

[14]  M. Wheeler,et al.  LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY , 2021 .

[15]  N. Smedira,et al.  Outcomes in Guideline‐Based Class I Indication Versus Earlier Referral for Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy , 2020, Journal of the American Heart Association.

[16]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[17]  T. Seidler,et al.  Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR Substudy Analysis. , 2020, Circulation.

[18]  S. Solomon,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[19]  E. Ashley,et al.  Silencing of MYH7 ameliorates disease phenotypes in human iPSC-Cardiomyocytes. , 2020, Physiological genomics.

[20]  S. Solomon,et al.  Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. , 2020, Journal of the American College of Cardiology.

[21]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[22]  T. Abraham,et al.  Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy , 2018, Journal of the American Heart Association.

[23]  C. Autore,et al.  Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. , 2017, International journal of cardiology.

[24]  R. Chan,et al.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients , 2017, Journal of the American Heart Association.

[25]  S. Markova,et al.  A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy , 2016, PloS one.

[26]  N. Smedira,et al.  Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. , 2015, Circulation. Cardiovascular imaging.

[27]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[28]  N. Smedira,et al.  Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract Obstruction , 2013, Circulation.

[29]  E. Argulian,et al.  Antihypertensive therapy in hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[30]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[31]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[32]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[33]  Y. Koga,et al.  Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. , 1986, Japanese heart journal.

[34]  C. Pollick.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. , 1982, The New England journal of medicine.

[35]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[36]  C. Oakley,et al.  Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy. , 1973, British heart journal.

[37]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.